Edition:
United Kingdom

Ocular Therapeutix Inc (OCUL.OQ)

OCUL.OQ on NASDAQ Stock Exchange Global Market

6.28USD
2:51pm GMT
Change (% chg)

$0.05 (+0.80%)
Prev Close
$6.23
Open
$6.36
Day's High
$6.38
Day's Low
$6.27
Volume
34,366
Avg. Vol
92,145
52-wk High
$11.79
52-wk Low
$3.30

Latest Key Developments (Source: Significant Developments)

Ocular Therapeutix Provides Legal Update
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Ocular Therapeutix Inc ::OCULAR THERAPEUTIX™ PROVIDES LEGAL UPDATE.OCULAR THERAPEUTIX INC - ON DEC. 21, CO WAS SERVED WITH A NEW DERIVATIVE COMPLAINT.OCULAR THERAPEUTIX - RECEIVED A SUBPOENA FROM SEC, DATED DEC 15, REQUESTING DOCUMENTS AND INFORMATION CONCERNING DEXTENZA 0.4 MG.  Full Article

Ocular Therapeutix posts Q3 loss per share $0.54
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Ocular Therapeutix Inc :Ocular Therapeutix reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.54.Q3 earnings per share view $-0.53 -- Thomson Reuters I/B/E/S.Ocular Therapeutix Inc - cash and cash equivalents at Sept 30, 2017 $51.2 million versus $32.9 million at Dec 31,2016‍​.Ocular Therapeutix - expects cash, cash equivalents to be enough to fund operating expenses, debt service obligations, capital expenditures into Q4 of 2018​.  Full Article

Ocular and Regeneron enter into strategic collaboration to develop sustained release formulation of aflibercept
Thursday, 13 Oct 2016 

Ocular Therapeutix Inc : Ocular Therapeutix(tm) and Regeneron enter into strategic collaboration to develop sustained release formulation of aflibercept for the treatment of wet AMD and other serious retinal diseases .Ocular Therapeutix Inc - eligible to receive up to $305 million in milestone payments in addition to royalties on potential future net sales.  Full Article

Ocular Therapeutix Q2 loss per share $0.46
Tuesday, 9 Aug 2016 

Ocular Therapeutix Inc : Ocular Therapeutix reports second quarter 2016 financial results and provides corporate update . Q2 loss per share $0.46 . Q2 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S .Says generated $441,000 in revenue during three months ended june 30, 2016 from product sales of resure sealant.  Full Article

Ocular therapeutix says FDA issued a letter noting 1 exception that relates to proposed process for Dextenza
Wednesday, 3 Aug 2016 

Ocular Therapeutix : Provides update on NDA for Dextenza for the treatment of post-surgical ocular pain . FDA issued a letter noting 1 exception that relates to proposed process for identity testing of incoming inert gas component used in manufacturing process . FDA issued a letter to co noting that corrective actions detailed in responses as whole appear to address ten inspectional observations . FDA also requested that co provide evidence when migration to automatic integration of analytical testing is complete, which is anticipated during Q3 .Working closely with FDA to address one remaining item and are planning for a resubmission to our NDA as soon as possible.  Full Article

Ocular Therapeutix gets complete response letter for dextenza NDA
Monday, 25 Jul 2016 

Ocular Therapeutix Inc : Ocular Therapeutix receives complete response letter from FDA for its NDA for dextenza for treatment of post-surgical ocular pain . Says no efficacy or safety issues raised by FDA .Concerns raised by FDA pertain to deficiencies in manufacturing process, controls identified during a pre-NDA approval inspection.  Full Article

Jennison Associates LLC reports 12 pct passive stake in Ocular Therapeutix
Friday, 8 Jul 2016 

Ocular Therapeutix Inc : Jennison Associates LLC reports 12 pct passive stake in Ocular Therapeutix as of June 30, 2016 - SEC Filing Source - http://bit.ly/29n5DRY Further company coverage: [OCUL.O] (Bengaluru Newsroom; +1 646 223 8780).  Full Article

Ocular Therapeutix posts test results of allergic conjunctivitis treatment
Monday, 6 Jun 2016 

Ocular Therapeutix Inc : Ocular Therapeutix(tm) announces topline results of second phase 3 clinical trial of Dextenza(tm) for the treatment of allergic conjunctivitis . Primary endpoint for ocular itching not achieved .There were no serious adverse events observed in second phase 3 clinical trial.  Full Article

Ocular Therapeutix Q1 loss per share $0.44
Tuesday, 10 May 2016 

Ocular Therapeutix Inc : Ocular Therapeutix reports first quarter 2016 financial results and provides corporate update . Q1 loss per share $0.44 . Q1 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S .Q1 revenue $458,000.  Full Article

BRIEF-Ocular Therapeutix Announces Kevin Hanley As Senior Vice President Technical Operations

* OCULAR THERAPEUTIX ANNOUNCES KEVIN HANLEY AS SENIOR VICE PRESIDENT, TECHNICAL OPERATIONS AND NAYMISHA PATEL AS VICE PRESIDENT OF QUALITY Source text for Eikon: Further company coverage: